Last updated on November 2017

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)


Brief description of study

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

Detailed Study Description

Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).

Clinical Study Identifier: TX4922

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Michele Shatz RN, BSN

Holy Cross Jim Moran Heart and Vascular Research Institute
Fort Lauderdale, FL USA
  Connect »